ClinicalTrials.gg
CompletedNCT00515203Updated Jul 25, 2014Results posted

Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

A Phase 1/2 interventional study of Placebo and AMG 531 in Idiopathic Thrombocytopenic Purpura, Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) and Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), sponsored by Amgen. Completed. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2014-07-25.

Sponsored by Amgen · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
22nd of 29
22 · median 62
Started
2007
the only one that year
Phase 1/2
3 of 29
none open now
Registered
9th of 29
by date
Lead sponsor
14 of 29
Amgen

Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 22nd largest by enrollment, is the only one that started in 2007, is one of 3 in phase 1/2, and was the 9th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of romiplostim (AMG 531) in the treatment of thrombocytopenia in pediatric subjects with chronic ITP. We will also evaluate the efficacy of romiplostim (AMG 531) and characterize the pharmacokinetics of romiplostim (AMG 531). It is anticipated that romiplostim (AMG 531), when given at an effective dose and schedule, will be well tolerated treatment for thrombocytopenia among pediatric subjects with chronic ITP.

03

Conditions studied

  • Idiopathic Thrombocytopenic Purpura
  • Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
  • Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Keywords

  • Immune (Idiopathic) Thrombocytopenic Purpura
  • Pediatric Idiopathic Thrombocytopenic Purpura
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Before any study-specific procedure, the appropriate written must be obtained. In addition to the written informed consent, the assent of the child from those subjects capable of providing assent must also be obtained if requested by the IRB/IEC.
  • Diagnosis of ITP according to The American Society of Hematology (ASH) Guidelines at least six months prior to screening
  • Age ≥ 12 months and \< 18 years at enrollment
  • The mean of two counts taken during the screening period must be ≤ 30 x 10\^9/L with no single count >35 x 10\^9/L
  • A serum creatinine concentration ≤ 1.5 times the laboratory normal range (for each age category)
  • Adequate liver function; serum ≤ 1.5 times the laboratory normal range
  • >10.0 g/dL

Exclusion criteria

Exclusion Criteria:

  • Known history of a bone marrow stem cell disorder (any abnormal bone marrow findings other than those typical of ITP must be approved by Amgen before a subject may be enrolled in the study)
  • Known history of venous or arterial thrombotic or thromboembolic event
  • Known history of congenital thrombocytopenia
  • Known history of except basal cell carcinoma
  • Known history of , , or
  • Known history of systemic lupus erythematosus, Evans Syndrome, or neutropenia
  • Known positive lupus anticoagulant or history of antiphospholipid antibody syndrome
  • Known history of Disseminated Intravascular Coagulation, Hemolytic Uremic Syndrome, or Thrombotic Thrombocytopenic Purpura
  • Currently receiving any treatment for ITP except for
  • IV Ig or anti-D Ig within two weeks prior to the screening visit
  • Rituximab (for any indication) within 14 weeks before the screening visit or anticipated use during the time of the proposed study
  • Splenectomy within eight weeks of the screening visit
  • Received hematopoietic growth factors including IL-11 (oprelvekin) within four weeks before the screening visit
  • Received any alkylating agents within eight weeks before the screening visit or anticipated use during the time of the proposed study
  • Subject is currently enrolled in or has not yet completed at least four weeks since ending other device or drug trial(s), or subject is receiving investigational agent(s)
  • Past or present participation in any study evaluating PEG-rHuMGDF, recombinant human thrombopoietin (rHuTPO), AMG 531, or related product
  • Pregnant (i.e. positive urine pregnancy test) or breast feeding
  • Subject is not using adequate precautions, if applicable.
  • Known to any recombinant E coli-derived product
  • Subject has any kind of disorder that compromises the ability to comply with all study procedures
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Placebo comparator
    II.

    5 thrombocytopenic (as defined per protocol) subjects

    Drug: Placebo

  • Experimental
    I.

    15 thrombocytopenic (as defined per protocol) subjects

    Drug: AMG 531

Interventions

  • DrugPlacebo

    Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.

  • Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.

    Also known as: romiplostim

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Occurrence of one or more adverse events in the participant during the 12-week treatment period

    Time frame: 12 weeks

Secondary outcomes

  1. Weeks With Platelet Count ≥ 50 x 10^9/L

    The number of weeks with platelet count ≥ 50 x 10\^9/L during the 12 week treatment period.

    Time frame: 12-week treatment period

  2. Bleeding Events (Grade 2 or Higher)

    Total number of bleeding events (Grade 2 or higher, i.e., mild to life-threatening, as defined in the protocol) for each participant during Weeks 2-13 (end-of-study visit for non-responders)

    Time frame: 12-week treatment period (Weeks 2 - 13)

  3. Platelet Count ≥ 50 x 10^9/L for Two Consecutive Weeks

    Participant incidence of achieving a platelet count ≥50 x 10\^9/L for two consecutive weeks during the 12 week treatment period.

    Time frame: 12-week treatment period

  4. Increase in Platelet Count ≥ 20 x 10^9/L Above Baseline for Two Consecutive Weeks

    Participant incidence of achieving an increase in platelet count ≥20 x 10\^9/L above baseline for two consecutive weeks during the 12 week treatment period.

    Time frame: 12-week treatment period

  5. Requirement for Rescue Therapy (as Defined Per Protocol)

    Participant required rescue therapy (as defined per protocol) during the 12 week treatment period.

    Time frame: 12-week treatment period

07

Results

Posted Mar 1, 2011

Participant flow

Participants were enrolled from 19 Jul 2007 through 11 November 2008

Participant flow — Overall Study
MilestoneRomiplostimPlacebo
Started175
Completed175
Not completed00

Outcome measures

SecondaryWeeks With Platelet Count ≥ 50 x 10^9/L

The number of weeks with platelet count ≥ 50 x 10\^9/L during the 12 week treatment period.

Time frame:
12-week treatment period
Reported as:
Mean · Weeks
Weeks With Platelet Count ≥ 50 x 10^9/L
WeeksRomiplostimPlacebo
Weeks With Platelet Count ≥ 50 x 10^9/L5.65 ± 3.000.00 ± 0.00
Statistical analysis
  • Romiplostim vs Placebo · Cochran-Mantel-Haenszel · p = 0.0019
SecondaryBleeding Events (Grade 2 or Higher)

Total number of bleeding events (Grade 2 or higher, i.e., mild to life-threatening, as defined in the protocol) for each participant during Weeks 2-13 (end-of-study visit for non-responders)

Time frame:
12-week treatment period (Weeks 2 - 13)
Reported as:
Mean · Events per participant
Bleeding Events (Grade 2 or Higher)
Events per participantRomiplostimPlacebo
Bleeding Events (Grade 2 or Higher)0.41 ± 1.000.00 ± 0.00
Statistical analysis
  • Romiplostim vs Placebo · Cochran-Mantel-Haenszel · p = 0.3651
SecondaryPlatelet Count ≥ 50 x 10^9/L for Two Consecutive Weeks

Participant incidence of achieving a platelet count ≥50 x 10\^9/L for two consecutive weeks during the 12 week treatment period.

Time frame:
12-week treatment period
Reported as:
Number · Participants
Platelet Count ≥ 50 x 10^9/L for Two Consecutive Weeks
ParticipantsRomiplostimPlacebo
Platelet Count ≥ 50 x 10^9/L for Two Consecutive Weeks150
Statistical analysis
  • Romiplostim vs Placebo · Fisher Exact · p = 0.0008
SecondaryIncrease in Platelet Count ≥ 20 x 10^9/L Above Baseline for Two Consecutive Weeks

Participant incidence of achieving an increase in platelet count ≥20 x 10\^9/L above baseline for two consecutive weeks during the 12 week treatment period.

Time frame:
12-week treatment period
Reported as:
Number · Participants
Increase in Platelet Count ≥ 20 x 10^9/L Above Baseline for Two Consecutive Weeks
ParticipantsRomiplostimPlacebo
Increase in Platelet Count ≥ 20 x 10^9/L Above Baseline for Two Consecutive Weeks150
Statistical analysis
  • Romiplostim vs Placebo · Fisher Exact · p = 0.0008
SecondaryRequirement for Rescue Therapy (as Defined Per Protocol)

Participant required rescue therapy (as defined per protocol) during the 12 week treatment period.

Time frame:
12-week treatment period
Reported as:
Number · Participants
Requirement for Rescue Therapy (as Defined Per Protocol)
ParticipantsRomiplostimPlacebo
Requirement for Rescue Therapy (as Defined Per Protocol)22
Statistical analysis
  • Romiplostim vs Placebo · Fisher Exact · p = 0.2098
PrimaryAdverse Events

Occurrence of one or more adverse events in the participant during the 12-week treatment period

Time frame:
12 weeks
Reported as:
Number · Participants
Adverse Events
ParticipantsRomiplostimPlacebo
Adverse Events165

Adverse events

Collected over 12 week treatment period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/5 (0%)5/5 (100%)
Romiplostim—1/17 (5.9%)16/17 (94.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboRomiplostim
InfluenzaInfections and infestations0/51/17
SepsisInfections and infestations0/51/17
Most frequent other events
Showing 10 of 54
Most frequent other events
EventPlaceboRomiplostim
VomitingGastrointestinal disorders2/52/17
HeadacheNervous system disorders2/56/17
CoughRespiratory, thoracic and mediastinal disorders2/52/17
Nasal congestionRespiratory, thoracic and mediastinal disorders2/50/17
EpistaxisRespiratory, thoracic and mediastinal disorders1/56/17
PyrexiaGeneral disorders0/54/17
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/54/17
Abdominal painGastrointestinal disorders1/51/17
Injection site haematomaGeneral disorders1/50/17
MalaiseGeneral disorders1/50/17

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RomiplostimPlaceboTotal
Mean9.4 ± 5.49.8 ± 4.69.5 ± 5.1
Sex: Female, Male
Sex: Female, Male(Participants)RomiplostimPlaceboTotal
Female426
Male13316
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RomiplostimPlaceboTotal
White or Caucasian9413
Black or African American505
Hispanic or Latino303
Other011
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011 Jul 7;118(1):28-36. doi: 10.1182/blood-2010-10-313908. Epub 2011 Apr 18. PubMed 21502541 ↗
  • Klaassen RJ, Mathias SD, Buchanan G, Bussel J, Deuson R, Young NL, Collier A, Bomgaars L, Blanchette V. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2012 Mar;58(3):395-8. doi: 10.1002/pbc.23312. Epub 2011 Sep 9. PubMed 21910213 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Mar 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2007
First posted
Aug 13, 2007
Start
Jul 2007
Primary completionActual
Mar 2009
CompletionActual
Aug 2009
Results first posted
Mar 1, 2011
Last update
Jul 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00515203
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 13, 2007
Start date
Jul 2007
Primary completion
Mar 2009
Completion
Aug 2009
Results posted
Mar 1, 2011
Last update
Jul 25, 2014

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion